Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while iShares 10 20 Year Treasury Bond ETF trades at $92.16 (market cap $11.02B). The key difference: iShares 10 20 Year Treasury Bond ETF is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| IOVA | TLH | |
|---|---|---|
Market Cap | $6.04B | $11.02B |
Volume | 14,805,993 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $14.82 | $105.36 |
52-Week Low | $1.81 | $91.34 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLH, an iShares 10-20 Year Treasury Bond ETF, trades at $92.19, up 0.81% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. Recent news highlights a challenging bond market environment, with Treasury yields reaching multi-decade highs, driving increased trading volume in the ETF. The fund continues its dividend distributions, with recent payments around $0.36-$0.38 per share.
The outlook for TLH is heavily influenced by the trajectory of long-term interest rates. Rising yields pressure bond prices, presenting headwinds, though the ETF offers income via dividends. Key risks include further Fed tightening and persistent inflation. Investors should weigh the income stability against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
